These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34347720)

  • 1. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
    Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D
    J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.
    de Vos L; Carrillo Cano TM; Zarbl R; Klümper N; Ralser DJ; Franzen A; Herr E; Gabrielpillai J; Vogt TJ; Dietrich J; Strieth S; Landsberg J; Dietrich D
    J Immunother; 2022 Sep; 45(7):324-334. PubMed ID: 35862127
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Vos L; Dietrich J; Strieth S; Bootz F; Dietrich D; Franzen A
    Immunotherapy; 2020 Aug; 12(12):903-920. PubMed ID: 32684057
    [No Abstract]   [Full Text] [Related]  

  • 4. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
    Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
    Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
    Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
    J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Yu S; Chen J; Chen X
    Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.
    Hoskins EL; Samorodnitsky E; Wing MR; Reeser JW; Hopkins JF; Murugesan K; Kuang Z; Vella R; Stein L; Risch Z; Yu L; Adebola S; Paruchuri A; Carpten J; Chahoud J; Edge S; Kolesar J; McCarter M; Nepple KG; Reilley M; Scaife C; Tripathi A; Single N; Huang RSP; Albacker LA; Roychowdhury S
    JCO Precis Oncol; 2023 Jan; 7():e2200300. PubMed ID: 36623238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
    Fu Y; Liu CJ; Kobayashi DK; Johanns TM; Bowman-Kirigin JA; Schaettler MO; Mao DD; Bender D; Kelley DG; Uppaluri R; Bi WL; Dunn IF; Tao Y; Luo J; Kim AH; Dunn GP
    Sci Rep; 2020 Jun; 10(1):9027. PubMed ID: 32493985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
    Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
    Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
    Röver LK; Gevensleben H; Dietrich J; Bootz F; Landsberg J; Goltz D; Dietrich D
    EBioMedicine; 2018 Feb; 28():97-104. PubMed ID: 29396294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
    Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
    Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.
    Takashima Y; Kawaguchi A; Sato R; Yoshida K; Hayano A; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Nakano M; Ogawa S; Tashiro K; Yamanaka R
    Sci Rep; 2019 Jul; 9(1):10004. PubMed ID: 31292525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
    Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
    Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.